Bertram Pitt
University of Michigan
Internal medicineEndocrinologyCardiologyIntensive care medicineMineralocorticoid receptorHazard ratioPlaceboSpironolactoneHeart failureCoronary artery diseaseAldosteroneKidney diseaseEplerenoneHyperkalemiaIn patientMyocardial infarctionDiabetes mellitusMedicineEjection fractionBlood pressure
841Publications
120H-index
66.7kCitations
Publications 836
Newest
#1Bertram Pitt (UM: University of Michigan)H-Index: 120
#2Frederic Jaisser (French Institute of Health and Medical Research)H-Index: 56
Last. George L. Bakris (U of C: University of Chicago)H-Index: 135
view all 3 authors...
Introduction null Resistant hypertension (RH) is more prevalent in the advanced stages of chronic kidney disease (CKD) and contributes to a greater likelihood of poor cardiovascular and renal outcomes. However, RH often goes untreated in this population as the currently available recommended add-on therapy, steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, may lead to unacceptable side effects, mainly hyperkalemia in a cohort with reduced kidney funct...
Source
#1Peter Rossing (Steno Diabetes Center)H-Index: 100
#2Rajiv Agarwal (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 85
Last. Andrea Z. Lage (Bayer)
view all 12 authors...
AIMS: Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the FIDELIO-DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the treatment effect of finerenone. MATERIALS AND METHODS: Patients with T2D, urine albumin-to-creatinine ratio (UACR) 30-5000 mg/g and estimated glomerular filtration rate (eGF...
1 CitationsSource
#1Su E Yeoh (Glas.: University of Glasgow)
#2Pooja Dewan (Glas.: University of Glasgow)H-Index: 8
Last. John J.V. McMurray (Glas.: University of Glasgow)H-Index: 197
view all 10 authors...
AIMS Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) individually cause significant morbidity and mortality. Their coexistence is associated with even worse outcomes, partly due to suboptimal heart failure therapy, especially underutilisation of beta-blockers. Our aim was to investigate outcomes in HFrEF patients with and without COPD, and the effects of mineralocorticoid receptor antagonists (MRAs) on outcomes. METHODS AND RESULTS We studied...
Source
#1Kazem RahimiH-Index: 59
#2Zeinab BidelH-Index: 8
Last. Larry AgodoaH-Index: 1
view all 102 authors...
Summary null Background null The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. null Methods null We did a meta-analysis using individual participant-level data from randomis...
2 CitationsSource
Source
Abstract Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kid...
6 CitationsSource
#1Muhammad Shariq Usman (UMMC: University of Mississippi Medical Center)
#2Bertram Pitt (UM: University of Michigan)H-Index: 120
Last. Javed Butler (UMMC: University of Mississippi Medical Center)H-Index: 30
view all 3 authors...
Source
#1Marcus Ståhlberg (Karolinska University Hospital)H-Index: 15
#2Ulrika Reistam (Karolinska University Hospital)
Last. Immo Weichert (Suffolk University)H-Index: 4
view all 12 authors...
In this paper we highlight the presence of tachycardia in Post-acute Covid-19 Syndrome by introducing a new label for this phenomenon: Post-covid-19 tachycardia syndrome and argue that this constitutes a phenotype or sub-syndrome in PACS. We also discuss epidemiology, putative mechanisms, treatment options and future research directions in this novel clinical syndrome.
Source
#1Adrienne-Denise V. Bilbao (UM: University of Michigan)
#2Jennifer R. Goldschmied (UM: University of Michigan)H-Index: 6
Last. Patricia J. Deldin (UM: University of Michigan)H-Index: 32
view all 10 authors...
Abstract null null Background null Major Depressive Disorder (MDD) has been linked in the literature to poorer prognosis in patients with cardiovascular dysfunction, although the mechanisms of this relationship remain unclear. Underlying Sleep Disordered Breathing (SDB) serves as a potential candidate to explain this effect due to its downstream effects on inflammatory activation and decreased nitric oxide (NO) bioavailability, both of which have been shown to contribute to the pathophysiology o...
Source
#1Patrick Rossignol (French Institute of Health and Medical Research)H-Index: 65
#2Bertram Pitt (UM: University of Michigan)H-Index: 120
Source